AM-Pharma Holding
Latest round
- Series D
Last raised
- Sep 2011
Total raised
- $62M
Investors
- 6
About AM-Pharma Holding
V.V. develops therapeutics for severe medical conditions, emphasizing cardiac surgery-associated renal damage and hypophosphatasia. Established in 2000 and headquartered in Utrecht, Netherlands, the company has completed 12 deals to date.AM-Pharma specializes in the development of therapeutics aimed at treating severe medical conditions, primarily focusing on cardiac surgery-associated renal damage (CSA-RD) and hypophosphatasia (HPP). Their flagship product, ilofotase alfa, is a proprietary compound designed to offer reno-protective effects for patients undergoing cardiac surgeries, addressing a significant complication that occurs in approximately 40% of such surgeries. The compound has demonstrated a proven safety profile and has been evaluated in global clinical trials with over 1,000 subjects. Additionally, AM-Pharma is advancing ilofotase alfa as a potential enzyme replacement therapy for HPP, an orphan disease characterized by impaired bone mineralization.AM-Pharma generates revenue through the development and potential commercialization of its therapeutic products, specifically ilofotase alfa. The company engages in business-to-business transactions primarily with healthcare institutions and specialized medical providers involved in cardiac surgery and the treatment of rare diseases. These transactions may include partnerships with hospitals for clinical trials and future sales of ilofotase alfa upon regulatory approval. The revenue model is structured around direct sales to healthcare providers, which would be initiated upon the successful launch of products in relevant markets.V. aims to expand its product offerings, particularly with the continued development of ilofotase alfa for both cardiac surgery-associated renal damage and hypophosphatasia. The company is also planning to extend its reach into new markets, targeting regions in North America and Europe by 2025.
Who invested in AM-Pharma Holding
6 investors across 3 rounds
See all investors in AM-Pharma Holding
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AM-Pharma Holding
Who invested in AM-Pharma Holding?
AM-Pharma Holding has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AM-Pharma Holding raised?
AM-Pharma Holding has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did AM-Pharma Holding last raise money?
AM-Pharma Holding's most recent round on record is a Series D, in Sep 2011.
What does AM-Pharma Holding do?
AM-Pharma Holding is a biotechnology company.
Where is AM-Pharma Holding headquartered?
AM-Pharma Holding is headquartered in Utrecht, Netherlands.
Which VCs invest in companies like AM-Pharma Holding?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at AM-Pharma Holding's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like AM-Pharma Holding? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.